
Citation: Boris G. Andryukov. Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19[J]. AIMS Microbiology, 2020, 6(3): 280-304. doi: 10.3934/microbiol.2020018
[1] | Kento Okuwa, Hisashi Inaba, Toshikazu Kuniya . Mathematical analysis for an age-structured SIRS epidemic model. Mathematical Biosciences and Engineering, 2019, 16(5): 6071-6102. doi: 10.3934/mbe.2019304 |
[2] | Kento Okuwa, Hisashi Inaba, Toshikazu Kuniya . An age-structured epidemic model with boosting and waning of immune status. Mathematical Biosciences and Engineering, 2021, 18(5): 5707-5736. doi: 10.3934/mbe.2021289 |
[3] | Mostafa Adimy, Abdennasser Chekroun, Claudia Pio Ferreira . Global dynamics of a differential-difference system: a case of Kermack-McKendrick SIR model with age-structured protection phase. Mathematical Biosciences and Engineering, 2020, 17(2): 1329-1354. doi: 10.3934/mbe.2020067 |
[4] | Hui Cao, Dongxue Yan, Ao Li . Dynamic analysis of the recurrent epidemic model. Mathematical Biosciences and Engineering, 2019, 16(5): 5972-5990. doi: 10.3934/mbe.2019299 |
[5] | Zhiping Liu, Zhen Jin, Junyuan Yang, Juan Zhang . The backward bifurcation of an age-structured cholera transmission model with saturation incidence. Mathematical Biosciences and Engineering, 2022, 19(12): 12427-12447. doi: 10.3934/mbe.2022580 |
[6] | Xiaohong Tian, Rui Xu, Ning Bai, Jiazhe Lin . Bifurcation analysis of an age-structured SIRI epidemic model. Mathematical Biosciences and Engineering, 2020, 17(6): 7130-7150. doi: 10.3934/mbe.2020366 |
[7] | Fang Zhang, Wenzhe Cui, Yanfei Dai, Yulin Zhao . Bifurcations of an SIRS epidemic model with a general saturated incidence rate. Mathematical Biosciences and Engineering, 2022, 19(11): 10710-10730. doi: 10.3934/mbe.2022501 |
[8] | Abdennasser Chekroun, Mohammed Nor Frioui, Toshikazu Kuniya, Tarik Mohammed Touaoula . Global stability of an age-structured epidemic model with general Lyapunov functional. Mathematical Biosciences and Engineering, 2019, 16(3): 1525-1553. doi: 10.3934/mbe.2019073 |
[9] | Maria Guadalupe Vazquez-Peña, Cruz Vargas-De-León, Jorge Velázquez-Castro . Global stability for a mosquito-borne disease model with continuous-time age structure in the susceptible and relapsed host classes. Mathematical Biosciences and Engineering, 2024, 21(11): 7582-7600. doi: 10.3934/mbe.2024333 |
[10] | Yicang Zhou, Zhien Ma . Global stability of a class of discrete age-structured SIS models with immigration. Mathematical Biosciences and Engineering, 2009, 6(2): 409-425. doi: 10.3934/mbe.2009.6.409 |
In the field of mathematical epidemiology, the SIR epidemic model is known as one of the most basic epidemic models, in which the host population is divided into three classes called susceptible, infective and removed [1]. In the study of epidemic models, the basic reproduction number R0 is one of the key concepts, and it is defined by the expected value of secondary cases produced by a typical infective individual in a totally susceptible population [2]. Mathematically, R0 is defined by the spectral radius of the next generation operator, and the method of numerical computation of R0 has been studied for structured epidemic models [3]. In a simple SIR epidemic model given by a system of ordinary differential equations, R0 completely determines the model dynamics in the sense of global stability of each equilibrium: If R0≤1, then the disease-free equilibrium is globally asymptotically stable, whereas if R0>1, then the endemic equilibrium is globally asymptotically stable [4, Section 5.5.2]. On the other hand, in some more complicated epidemic models, a stable endemic equilibrium can exist even if R0<1 due to a backward bifurcation [5]. Also, an endemic equilibrium can be destabilized, and a stable periodic solution can arise for R0>1 due to a Hopf bifurcation [6]. Periodic solutions in epidemic models have attracted much attention because they can describe non-seasonal oscillations of epidemics. Some of the known causes of the periodicity in epidemic models are periodic coefficients, time delay, nonlinear incidence and age structure [7,8,9,10]. In this study, we consider the periodicity in an age-structured SIR epidemic model. Age-structured epidemic models have been widely applied for epidemiological considerations in the era of COVID-19 [11].
In the field of mathematical epidemiology, the time elapsed since the infection is called the infection age, whereas the time elapsed since the birth is called the chronological age. For an infection age-structured SIR epidemic model, a complete threshold property of R0 in the sense of the global stability of each equilibrium was shown by constructing a suitable Lyapunov function [12]. In contrast, for a chronological age-structured SIR epidemic model, the complete threshold property of R0 does not hold in general. More precisely, although the global stability of the disease-free equilibrium for R0<1 was proved in [13], some additional conditions were needed to guarantee the local or global asymptotic stability of the endemic equilibrium for R0>1 [13,14], and the possibility of the instability of the endemic equilibrium for R0>1 was studied in [15,16,17,18].
In [15], Thieme showed that the unique endemic equilibrium can be unstable for R0>1 in a chronological age-structured SIR epidemic model with age-dependent infectivity. However, the existence of periodic solutions and the occurrence of Hopf bifurcation have not yet been proved for this model. The purpose of this study is to tackle this problem when the transmission rate has a specific form. More precisely, we assume that the transmission rate is a shifted exponential function (see (A5) in the next section) and perform a Hopf bifurcation analysis regarding the infimum of the support of the function as a bifurcation parameter. Epidemiologically, such a shifted exponential function represents the case where infected people do not have infectivity until a certain critical age, and the infectivity decreases in an exponential sense after the critical age. This function enables us to consider a special case studied in [15], where the product of the transmission rate and the stable age distribution is highly concentrated in a particular age class. In this paper, we obtain concrete sufficient conditions for a Hopf bifurcation.
This paper is organized as follows: In Section 2, we introduce the model in this study. In Section 3, we give some preliminaries for the analysis, including the existence and uniqueness of the endemic equilibrium for R0>1. In Section 4, we perform a Hopf bifurcation analysis for a special case where the force of infection in the steady state is equal to the removal rate. We show that there always exists a critical value such that a Hopf bifurcation occurs when the bifurcation parameter reaches it. In Section 5, we perform a more general analysis for the case where the force of infection in the steady state is not equal to the removal rate. We obtain a similar Hopf bifurcation result as in Section 4 when the distance between the force of infection and the removal rate is sufficiently small. Moreover, we numerically confirm a special case where the stability switch of the endemic equilibrium occurs more than once. Finally, Section 6 is devoted to a discussion.
Let S(t,a), I(t,a) and R(t,a) be the susceptible, infective and removed populations of age a at time t, respectively. In this paper, we consider the following SIR epidemic model with chronological age structure:
{(∂∂t+∂∂a)S(t,a)=−Λ(t)S(t,a)−μ(a)S(t,a),t>0, a>0,(∂∂t+∂∂a)I(t,a)=Λ(t)S(t,a)−[μ(a)+γ]I(t,a),t>0, a>0,(∂∂t+∂∂a)R(t,a)=γI(t,a)−μ(a)R(t,a),t>0, a>0,S(t,0)=∫∞0b(a)P(t,a)da,I(t,0)=0,R(t,0)=0,t>0, | (2.1) |
where μ(a) is the mortality rate, γ is the removal rate, b(a) is the birth rate, P(t,a):=S(t,a)+I(t,a)+R(t,a) is the population age density, and
Λ(t):=1∫∞0P(t,a)da∫∞0β(a)I(t,a)da |
is the force of infection with the transmission rate β(a). We assume γ>0, and the following
(A1) μ∈L1+,loc(0,∞), and ∫∞0μ(a)da=∞.
(A2) ∫∞0b(a)ℓ(a)da=1, where ℓ(a):=e−∫a0μ(σ)dσ is the survival probability.
(A3) The population has attained the stable age distribution, that is, P(t,a)=P∗(a):=Nℓ(a)/L for all t>0 and a>0, where N>0 is the stationary population size, and L:=∫∞0ℓ(a)da is the life expectancy.
Let
˜S(t,a):=S(t,a)P∗(a),˜I(t,a):=I(t,a)P∗(a). |
For notational simplicity, dropping the tildes on ˜S and ˜I, we obtain the following normalized SI system:
{(∂∂t+∂∂a)S(t,a)=−Λ(t)S(t,a),t>0, a>0,(∂∂t+∂∂a)I(t,a)=Λ(t)S(t,a)−γI(t,a),t>0, a>0,S(t,0)=1,I(t,0)=0,t>0, | (2.2) |
where
Λ(t)=1N∫∞0β(a)P∗(a)I(t,a)da. |
Note that these S and I are the normalized age-densities satisfying 0≤S,I≤1, and we can omit the equation of R as it does not affect the dynamics of system (2.2).
In [15], Thieme investigated the stability of the endemic equilibrium of system (2.2) when it uniquely exists. He analytically showed that it can be destabilized if β(a)P∗(a) is highly concentrated in a particular age class. However, the problem of the existence of periodic solutions when the endemic equilibrium is unstable was unsettled. In this paper, we deal with this problem by applying the method of local Hopf bifurcation theory. In [15], it was assumed that there exist constants c1,c2>0 such that β(a)ℓ(a)≤c1e−c2a for all a>0. In this paper, we make the following additional assumptions:
(A4) μ(a)=μ>0 for all a>0.
(A5) There exist β0>0 and τ,k≥0 such that
β(a)={0,a<τ,β0e−ka,a≥τ. |
In other words, the transmission rate β(a) is a shifted exponential function. One can then see that β(a)ℓ(a)≤c1e−c2a for all a>0 holds for c1=β0 and c2=μ+k. If both β0 and k are large, we can say that β(a)P∗(a) is highly concentrated in a particular age τ as in the case studied in [15]. Here, we remark that we can consider a different situation where β(a)P∗(a) is exponentially distributed for a≥τ. Regarding τ as a bifurcation parameter, we investigate the existence of a critical value τc>0 such that a Hopf bifurcation occurs, and a periodic solution bifurcates from the endemic equilibrium when τ=τc.
Let X:=L1(0,a†) and X+:=L1+(0,a†). It is easy to see that system (2.2) always has the disease-free equilibrium E0=(1,0)∈X+×X+. Let E∗=(S∗,I∗) denote an endemic equilibrium of system (2.2). It then holds
{dS∗(a)da=−Λ∗S∗(a),a>0,dI∗(a)da=Λ∗S∗(a)−γI∗(a),a>0,S∗(0)=1,I∗(0)=0, | (3.1) |
where the endemic force of infection obeys
Λ∗=1N∫∞0β(a)P∗(a)I∗(a)da. | (3.2) |
Solving (3.1), we obtain
S∗(a)=e−Λ∗a,I∗(a)=∫a0e−γ(a−σ)Λ∗S∗(σ)dσ=Λ∗e−γa∫a0e(γ−Λ∗)σdσ. | (3.3) |
Substituting the equation of I∗ into the right-hand side of (3.2) and dividing both sides by Λ∗, we obtain
1=1N∫∞0β(a)P∗(a)e−γa∫a0e(γ−Λ∗)σdσda. | (3.4) |
Since the right-hand side of (3.4) is monotone decreasing for Λ∗, we see that a unique Λ∗>0 satisfying (3.4) exists if and only if R0>1, where
R0=1N∫∞0β(a)P∗(a)e−γa∫a0eγσdσda=1γN∫∞0β(a)P∗(a)(1−e−γa)da |
is the basic reproduction number [2] for system (2.2). More precisely, we obtain the following proposition.
Proposition 3.1. If R0>1, then system (2.2) has a unique endemic equilibrium E∗=(S∗,I∗)∈X+×(X+∖{0}).
Proof. As explained above, if R0>1, then there exists a unique Λ∗>0 such that (3.4) is satisfied. We then obtain S∗(a) and I∗(a) from (3.3). This completes the proof.
In what follows, we assume R0>1 and investigate the local stability of the endemic equilibrium E∗. Let
U(t,a):=S(t,a)−S∗(a),V(t,a):=I(t,a)−I∗(a), |
be the perturbation from E∗. We then have the following linearized system.
{(∂∂t+∂∂a)U(t,a)=−Λ∗U(t,a)−S∗(a)N∫∞0β(a)P∗(a)V(t,a)da,t>0, a>0,(∂∂t+∂∂a)V(t,a)=Λ∗U(t,a)+S∗(a)N∫∞0β(a)P∗(a)V(t,a)da−γV(t,a),t>0, a>0,U(t,0)=0,V(t,0)=0,t>0. | (3.5) |
Substituting U(t,a)=eλtu(a) and V(t,a)=eλtv(a)(λ∈C) into (3.5) and dividing each equation by eλt, we have
{(λ+dda)u(a)=−Λ∗u(a)−wS∗(a),a>0,(λ+dda)v(a)=Λ∗u(a)+wS∗(a)−γv(a),a>0,u(0)=0,v(0)=0,w=1N∫∞0β(a)P∗(a)v(a)da. | (3.6) |
We first show that λ=0 is not an eigenvalue.
Lemma 3.1. If λ=0, then there exists no (u,v)≠(0,0) satisfying (3.6).
Proof. For λ=0, recalling that S∗(a)=e−Λ∗a, we obtain
u(a)=∫a0e−Λ∗(a−σ)[−wS∗(σ)]dσ=−we−Λ∗aa,v(a)=∫a0e−γ(a−σ)[Λ∗u(σ)+wS∗(σ)]dσ=we−γa∫a0e(γ−Λ∗)σ(1−Λ∗σ)dσ. |
Substituting the equation of v(a) into w=N−1∫∞0β(a)P∗(a)v(a)da and dividing both sides by w, we have
1=1N∫∞0β(a)P∗(a)e−γa∫a0e(γ−Λ∗)σ(1−Λ∗σ)dσda. |
However, by (3.4), we have
1N∫∞0β(a)P∗(a)e−γa∫a0e(γ−Λ∗)σ(−Λ∗σ)dσda=0, |
which is a contradiction. This completes the proof.
By Lemma 3.1, we can focus on λ≠0. Recalling that S∗(a)=e−Λ∗a, we obtain
u(a)=−w∫a0e−(λ+Λ∗)(a−σ)S∗(σ)dσ=−we−Λ∗a1−e−λaλ,v(a)=∫a0e−(λ+γ)(a−σ)[Λ∗u(σ)+wS∗(σ)]dσ=we−(λ+γ)a∫a0e(λ+γ−Λ∗)σ(1−Λ∗1−e−λσλ)dσ=we−(λ+γ)aλ∫a0[(λ−Λ∗)e(λ+γ−Λ∗)σ+Λ∗e(γ−Λ∗)σ]dσ. |
Substituting the equation of v(a) into w=∫∞0β(a)P∗(a)v(a)da and dividing both sides by w, we have
1=1N∫∞0β(a)P∗(a)e−(λ+γ)aλ∫a0[(λ−Λ∗)e(λ+γ−Λ∗)σ+Λ∗e(γ−Λ∗)σ]dσda. |
Under assumptions (A4) and (A5), this equation can be rewritten as
1=β1λ∫∞τe−(λ+p)a∫a0[(λ−Λ∗)e(λ+γ−Λ∗)σ+Λ∗e(γ−Λ∗)σ]dσda, | (3.7) |
where β1:=β0/L and p:=k+μ+γ. Eq (3.7) is the starting point of our Hopf bifurcation analysis.
We now consider a special case where Λ∗=γ. In this case, Eq (3.7) can be rewritten as
1=β1λ∫∞τe−(λ+p)a∫a0[(λ−γ)eλσ+γ]dσda. | (4.1) |
Since we are interested in a Hopf bifurcation at which Reλ=0, we restrict our attention to λ such that Reλ>−p. We can then rewrite (4.1) as
1=β1λ∫∞τe−(λ+p)a[λ−γλ(eλa−1)+γa]da=β1λ2[(λ−γ)(e−pτp−e−(λ+p)τλ+p)+γλe−(λ+p)τλ+p(τ+1λ+p)]. | (4.2) |
On the other hand, from Eq (3.4), we have
1=β1∫∞τae−pada=β1(τp+1p2)e−pτ, |
and thus,
β1=p2epτpτ+1. | (4.3) |
Substituting (4.3) into (4.2), we obtain
1=p2(pτ+1)λ2[(λ−γ)(1p−e−λτλ+p)+γλe−λτλ+p(τ+1λ+p)]=1(pτ+1)λ2(λ+p)2{p(λ−γ)(λ+p)2+p2[−(λ−γ)(λ+p)+γτλ(λ+p)+γλ]e−λτ}, |
which is equivalent to
(pτ+1)λ2(λ+p)2=p(λ−γ)(λ+p)2+p2[−(λ−γ)(λ+p)+γτλ(λ+p)+γλ]e−λτ. |
Hence, we obtain the following characteristic equation:
a4λ4+a3λ3+a2λ2+a1λ+a0+(b2λ2+b1λ+b0)e−λτ=0, | (4.4) |
where
a4=pτ+1,a3=2p2τ+p,a2=p3τ−p2+γp,a1=−p3+2γp2,a0=γp3,b2=−γp2τ+p2,b1=−γp3τ+p3−2γp2,b0=−γp3. |
Note that although λ=0 satisfies (4.4), we can disregard it by virtue of Lemma 3.1. We now prove the following lemma.
Lemma 4.1. If τ=0, then all nonzero roots λ of the characteristic Eq (4.4) have negative real parts.
Proof. If τ=0, Eq (4.4) can be rewritten as λ4+pλ3+γpλ2=0. As λ≠0, dividing both sides by λ2, we have λ2+pλ+γp=0. We then easily see that all λ have negative real parts because p and γp are strictly positive. This completes the proof.
Lemmas 3.1 and 4.1 imply that the endemic equilibrium E∗, which uniquely exists under R0>1, is locally asymptotically stable if τ=0. By the continuity, E∗ is locally asymptotically stable for small τ>0. In what follows, we investigate the existence of a τc>0 such that E∗ is locally asymptotically stable for τ∈[0,τc) and destabilized at τ=τc.
We now seek a pair of simple pure imaginary roots λ=±iω (ω>0) of the characteristic Eq (4.4). Since all coefficients in (4.4) are real, if λ=iω satisfies (4.4), then λ=−iω also satisfies (4.4). Therefore, we focus on λ=iω. Substituting λ=iω into (4.4), we have
a4ω4−ia3ω3−a2ω2+ia1ω+a0+(−b2ω2+ib1ω+b0)e−iωτ=0. |
As e−iωτ=cosωτ−isinωτ, we obtain the following two equations for real and imaginary parts, respectively:
{a4ω4−a2ω2+a0=(b2ω2−b0)cosωτ−b1ωsinωτ,a3ω3−a1ω=b1ωcosωτ+(b2ω2−b0)sinωτ. | (4.5) |
Taking squares of both sides in the two equations of (4.5) and adding them, we obtain
(a4ω4−a2ω2+a0)2+(a3ω3−a1ω)2=(b2ω2−b0)2+b21ω2. |
Rearranging this equation, we obtain
ω2[c3(ω2)3+c2(ω2)2+c1ω2+c0]=0 | (4.6) |
(note that a20−b20=0), where
c3=a24,c2=−2a2a4+a23,c1=2a0a4+a22−2a1a3−b22,c0=−2a0a2+a21+2b0b2−b21. |
As we can rule out ω=0 by Lemma 3.1, dividing both sides of (4.6) by ω2, we obtain
c3(ω2)3+c2(ω2)2+c1ω2+c0=0. | (4.7) |
On the existence of a positive ω>0 satisfying (4.7), we prove the following lemma:
Lemma 4.2. The Eq (4.7) has a unique nonzero positive root ω>0.
Proof. Let h(x)=c3x3+c2x2+c1x+c0. It suffices to show that h(x)=0 has a unique positive root x∗>0, for which ω=√x∗>0 is the desired root of (4.7). It is obvious that c3=(pτ+1)2>0. Moreover, we have, using p=k+μ+γ>γ,
c2=−2(p3τ−p2+γp)(pτ+1)+(2p2τ+p)2=2p4τ2+4p3τ+3p2−2γp(pτ+1)>2p4τ2+4p3τ+3p2−2p2(pτ+1)=2p4τ2+2p3τ+p2>0, |
and, using b0=−a0 and b1=−γp3τ−a1,
c0=−2a0(a2+b2)+a21−(γp3τ+a1)2=−2γp3(p3τ+γp−γp2τ)−γ2p6τ2−2γp3τa1=−2γp3(p3τ+γp−γp2τ)−γ2p6τ2−2γp3τ(−p3+2γp2)=−2γ2p4−2γ2p5τ−γ2p6τ2<0. |
c0<0 and c2,c3>0 imply that h(x)=0 has a unique positive root x∗>0. This completes the proof.
The following corollary will be used in the proof of the transversality:
Corollary 4.1. Let h(x) and x∗ be as defined in the proof of Lemma 4.2. Then, h′(x∗)>0.
Proof. The assertion immediately follows from c0<0 and c2,c3>0.
Note that since a2,a3,a4,b1 and b2 in (4.4) depend on τ, the root ω also depends on τ: ω=ω(τ). Since (4.7) is a necessary condition for λ=iω to be a root of (4.4), we have to find a τc>0 such that ω(τc) satisfies not only (4.7) but also (4.5). By (4.5), we have
{cosωτ=(a4ω4−a2ω2+a0)(b2ω2−b0)+(a3ω3−a1ω)b1ω(b2ω2−b0)2+b21ω2=:φ,sinωτ=−(a4ω4−a2ω2+a0)b1ω+(a3ω3−a1ω)(b2ω2−b0)(b2ω2−b0)2+b21ω2=:ψ. | (4.8) |
We define θ∈(0,2π] by
θ:={arccosφ,ψ>0,2π−arccosφ,ψ≤0. |
It then follows from (4.8) that ωτ=θ, and thus,
τ=θω. |
Note that φ, ψ and θ also depend on τ. Let f(τ):=θ(τ)/ω(τ). Then, the desired τc is a positive fixed point of f: τc=f(τc). Before proving the existence of such τc, we give the following lemma:
Lemma 4.3. For coefficients c0,c1,c2 and c3, it holds that
limτ→∞1(pτ)2(c0c1c2c3)=(−γ2p4p2(p2−γ2)2p21). |
Proof. The convergence of ci/(pτ)2 (i=0,2,3) can be easily checked by using the expressions of c0,c2 and c3 given in the proof of Lemma 4.2. For c1, we have
c1=2γp3(pτ+1)+(p3τ−p2+γp)2−2(−p3+2γp2)(2p2τ+p)−(−γp2τ+p2)2=2γp4τ+2γp3+p6τ2+p4+γ2p2−2p5τ+2γp4τ−2γp3+4p5τ+2p4−8γp4τ−4γp3−γ2p4τ2+2γp4τ−p4=−2γp4τ−4γp3+p6τ2+γ2p2+2p5τ+2p4−γ2p4τ2=(p2−γ2)p4τ2+2(p−γ)p4τ−4γp3+γ2p2+2p4=p2[(p2−γ2)p2τ2+2(p−γ)p2τ−4γp+γ2+2p2], |
and hence, limτ→∞c1/(pτ)2=p2(p2−γ2). This completes the proof.
We now prove the following proposition:
Proposition 4.1. There exists a τc>0 such that λ=±iω(τc) is a pair of simple pure imaginary roots of the characteristic Eq (4.4).
Proof. By Lemma 4.2 and its proof, one can see that ω(τ) is continuous and finite for all τ≥0. Thus, θ(τ) and f(τ) are also continuous and finite for all τ≥0. Moreover, it follows that f(0)=θ(0)/ω(0)>0. Hence, by the continuity, if limτ→∞f(τ)<∞, then we can conclude that there exists a τc>0 such that τc=f(τc).
Let {τn}∞n=1 be an increasing sequence in (0,∞), and let ωn:=ω(τn). By dividing both sides of (4.7) by (pτn)2, we have
c3(pτn)2(ω2n)3+c2(pτn)2(ω2n)2+c1(pτn)2ω2n+c0(pτn)2=0. |
By Lemma 4.3, we see that {ωn}∞n=1 converges to ω∞, which is the unique positive root of the following equation:
(ω2∞)3+2p2(ω2∞)2+p2(p2−γ2)ω2∞−γ2p4=0. |
Thus, we have limτ→∞f(τ)≤2π/ω∞<∞. This completes the proof.
Proposition 4.1 guarantees the existence of a pair of pure imaginary roots at τ=τc>0.
We next investigate the transversality condition at τ=τc, that is,
dReλdτ|λ=iωc>0, | (4.9) |
where ωc:=ω(τc). Following a general result given by [19], we define g(τ):=τ−f(τ). Now, we have the following proposition.
Proposition 4.2. If g′(τc)>0, then (4.9) holds.
Proof. Let y(ω) be the left-hand side of (4.6):
y(ω):=ω2[c3(ω2)3+c2(ω2)2+c1ω2+c0]=ω2h(ω2). |
Following a calculation in [19, Proof of Theorem 2.2] for a general characteristic equation, we can obtain a similar result as in [19, Theorem 2.2]:
sign{dReλdτ|λ=iωc}=sign{∂y(ωc)∂ω} sign{g′(τc)}. |
Note that from Lemma 4.2 and Corollary 4.1, it follows that h(ω2c)=0 and h′(ω2c)>0. We then have that
∂y(ωc)∂ω=2ωch(ω2c)+ω2ch′(ω2c)2ωc=2ω3ch′(ω2c)>0. |
Hence, we have
sign{dReλdτ|λ=iωc}=sign{g′(τc)}. |
This completes the proof.
As shown in the proof of Proposition 4.1, we have f(0)>0 and limτ→∞f(τ)<∞. This implies that there exists at least one τc>0 such that g(τc)=τc−f(τc)=0 and g′(τc)>0. That is, a Hopf bifurcation is always possible in model (2.2) with R0>1 and Λ∗=γ. More precisely, we obtain the following main result:
Proposition 4.3. Suppose that β1 depends on τ as for (4.3). Then, R0>1 and Λ∗=γ hold for all τ≥0, and there exists a τc>0 such that a pair of simple pure imaginary roots ±iω(τc) ( = ±iωc) satisfies the characteristic Eq (4.4) and crosses the imaginary axis from left to right as τ increases over τc.
Under the condition in Proposition 4.3, there always exists a critical value τc>0 such that a Hopf bifurcation occurs, and a periodic solution arises when the infimum τ of the support of function β(a) reaches τ=τc. In the next subsection, we numerically confirm this result.
For simplicity, we fix μ=γ=k=1. Note that these parameters are technically chosen in order to confirm the validity of Proposition 4.3, and thus, there is no biological reason for this choice. In this case, p=3, and we can numerically calculate functions ω(τ), θ(τ), f(τ) and g(τ), and τc≈3.84 as shown in Figure 2. Note that L=1/μ=1, and the force of infection is
Λ(t)=1N∫∞0β(a)P∗(a)I(t,a)da=β0L∫∞τe−(k+μ)aI(t,a)da=β0∫∞τe−(k+μ)aI(t,a)da. |
It then follows from (4.3) that β0=β1=p2epτ/(pτ+1). For the normalized system (2.2), we choose the initial condition as S(0,a)=0.99 and I(0,a)=0.01 for all a>0.
For τ=3.7<τc, we see in Figure 3 that the numerical solutions of I(t,a) and Λ(t) converge to the positive steady states I∗(a) and Λ∗, respectively. In particular, we can confirm that Λ∗=γ=1 in Figure 3 (b).
For τ=4>τc, we see in Figure 4 that the numerical solutions of I(t,a) and Λ(t) do not converge to the positive steady states but to positive periodic solutions.
Thus, we can conclude that a Hopf bifurcation occurs at τ=τc. In this case, the outbreaks occur periodically if the length τ of the period with no infectivity is sufficiently large.
We next consider the case where Λ∗≠γ. Let q:=γ−Λ∗≠0. Note that p−q=k+μ+Λ∗>0. As in the previous section, since we are interested in a Hopf bifurcation at which Reλ=0, we restrict our attention to λ such that Reλ>max(−p,−(p−q)) and λ≠−q. Equation (3.7) can then be rewritten as
1=β1λ∫∞τe−(λ+p)a∫a0[(λ−Λ∗)e(λ+q)σ+Λ∗eqσ]dσda=β1λ∫∞τ[λ−Λ∗λ+q(e−(p−q)a−e−(λ+p)a)+Λ∗q(e−(λ+p−q)a−e−(λ+p)a)]da=β1λ[λ−Λ∗λ+q(e−(p−q)τp−q−e−(λ+p)τλ+p)+Λ∗q(e−(λ+p−q)τλ+p−q−e−(λ+p)τλ+p)]. | (5.1) |
On the other hand, Eq (3.4) can be rewritten as
1=β1∫∞τe−pa∫a0eqσdσda=β1q∫∞τ(e−(p−q)a−e−pa)da=β1q(e−(p−q)τp−q−e−pτp). |
Thus, we have
β1=pq(p−q)epτpeqτ−(p−q). | (5.2) |
Let Q=Q(q,τ):=(eqτ−1)/q. Note that Q(q,τ)>0 for all q∈R∖{0} and τ>0, and
limq→0Q(q,τ)=τ for each fixed τ>0,limτ→0Q(q,τ)=0 for each fixed q≠0. |
(5.2) can then be rewritten as
β1=p(p−q)epτpQ+1. | (5.3) |
Substituting this β1 into (5.1) and rearranging it, we obtain
(pQ+1)λ=p(p−q)[λ−Λ∗λ+q(eqτp−q−e−λτλ+p)+Λ∗q(e−(λ−q)τλ+p−q−e−λτλ+p)]=peqτλ−Λ∗λ+q+p(p−q)[−λ−Λ∗(λ+p)(λ+q)+Λ∗qeqτ(λ+p)−(λ+p−q)(λ+p)(λ+p−q)]e−λτ. |
We then have
(pQ+1)λ−peqτλ−Λ∗λ+q+p(p−q)[λ−Λ∗(λ+p)(λ+q)−Λ∗qeqτ(λ+p)−(λ+p−q)(λ+p)(λ+p−q)]e−λτ=0. |
Multiplying by (λ+p)(λ+q)(λ+p−q) on both sides, we obtain
(pQ+1)λ(λ+p)(λ+q)(λ+p−q)−peqτ(λ−Λ∗)(λ+p)(λ+p−q)+p(p−q){(λ−Λ∗)(λ+p−q)+Λ∗q[(1−eqτ)λ+p−q−peqτ](λ+q)}e−λτ=0. |
Note that eqτ=qQ+1. We then have
(pQ+1)λ(λ+p)(λ+q)(λ+p−q)−p(qQ+1)(λ−Λ∗)(λ+p)(λ+p−q)+p(p−q){(λ−Λ∗)(λ+p−q)−Λ∗(Qλ+pQ+1)(λ+q)}e−λτ=0. |
It can be rewritten as
A4λ4+A3λ3+A2λ2+A1λ+A0+(B2λ2+B1λ+B0)e−λτ=0, | (5.4) |
where
A4=pQ+1,A3=(2p−q)pQ+p,A2=[p(p−q)+Λ∗q]pQ+Λ∗p−(p−q)2,A1=−p(p−q)2+Λ∗(2p−q)p(qQ+1),A0=Λ∗p2(p−q)(qQ+1),B2=p(p−q)(1−Λ∗Q),B1=p(p−q)2−Λ∗p(p−q)(2+pQ+qQ),B0=−Λ∗p2(p−q)(qQ+1). |
We can check that (5.4) is equivalent to (4.4) if q→0. In fact, we have the following lemma:
Lemma 5.1. For each fixed τ>0, it holds that
limq→0(A4,A3,A2,A1,A0,B2,B1,B0)=(a4,a3,a2,a1,a0,b2,b1,b0). | (5.5) |
Proof. For each fixed τ>0, recalling that limq→0(Q,Λ∗)=(τ,γ), we obtain
limq→0A4=pτ+1=a4,limq→0A3=2p2τ+p=a3,limq→0A2=p3τ+γp−p2=a2,limq→0A1=−p3+2γp2=a1,limq→0A0=γp3=a0,limq→0B2=p2(1−γτ)=b2,limq→0B1=p3−γp2(2+pτ)=b1,limq→0B0=−γp3=b0. |
This completes the proof.
By Proposition 4.3 and Lemma 5.1, regarding τ as a bifurcation parameter, we see that a Hopf bifurcation can occur as in Section 4 if |q| is sufficiently small. More precisely, we obtain the following corollary:
Corollary 5.1. Suppose that q≠0, |q| is sufficiently small, and β1 depends on τ as for (5.3). Then, R0>1 and Λ∗=γ−q>0 hold for all τ≥0, and there exists a τc>0 such that a pair of simple pure imaginary roots ±iΩ(τc)(=±iΩc) satisfies the characteristic Eq (5.4) and crosses the imaginary axis from left to right as τ increases over τc.
We next proceed to a more general case where |q| is not small. We can prove the following lemma, which corresponds to Lemma 4.1.
Lemma 5.2. If τ=0, then all roots λ except 0 and −q of the characteristic Eq (5.4) have negative real parts.
Proof. If τ=0, then Q=0, and the characteristic Eq (5.4) can be rewritten as
λ4+pλ3+[q(p−q)+Λ∗p]λ2+Λ∗pqλ=0. |
This equation is equivalent to
λ(λ+q)[λ2+rλ+Λ∗p]=0. |
If λ≠0,−q, then we have
λ2+(p−q)λ+Λ∗p=0. |
We then see that all roots λ have negative real parts because p−q>0 and Λ∗p>0. This completes the proof.
Using Lemma 5.2, we prove the following proposition on the local asymptotic stability of E∗ for τ=0:
Proposition 5.1. If R0>1, q≠0 and τ=0, then the endemic equilibrium E∗ of system (2.2) is locally asymptotically stable.
Proof. By Lemma 5.2, it suffices to show that λ=0 and −q do not affect the stability of E∗. In fact, by Lemma 3.1, λ=0 cannot be a characteristic eigenvalue. If q>0, then λ=−q does not affect the stability of the endemic equilibrium E∗. If q<0, substituting λ=−q into the first equation in (5.1), we obtain, for τ=0,
1=β1−q∫∞0e−(p−q)a[−(q+Λ∗)a+Λ∗q(eqa−1)]da=β1γq∫∞0ae−(p−q)ada+β1Λ∗q2∫∞0[e−(p−q)a−e−(p−2q)a]da=β1γq1(p−q)2+β1Λ∗q2(1p−q−1p−2q)=β1q(p−q)(γp−q−Λ∗p−2q)=β1(p−q−γ)(p−q)2(p−2q). |
Since β1=p(p−q) for τ=0, we have
1=p(p−q−γ)(p−q)(p−2q)<(p−2q)(p−q)(p−q)(p−2q)=1, |
which is a contradiction (note that p<p−2q as q<0). Hence, λ≠−q. This completes the proof.
As in Section 4.1, substituting λ=iΩ (Ω>0) into (5.4), we obtain
A4Ω4−iA3Ω3−A2Ω2+iA1Ω+A0+(−B2Ω2+iB1Ω+B0)e−iΩτ=0. |
Dividing this equation into real and imaginary parts, we have
{A4Ω4−A2Ω2+A0=(B2Ω2−B0)cosΩτ−B1ΩsinΩτ,A3Ω3−A1Ω=B1ΩcosΩτ+(B2Ω2−B0)sinΩτ. | (5.6) |
Taking squares of both sides in the two equations and adding them, we obtain
(A4Ω4−A2Ω2+A0)2+(A3Ω3−A1Ω)2=(B2Ω2−B0)2+B21Ω2. |
Rearranging this equation, we have
Ω2[C3(Ω2)3+C2(Ω2)2+C1Ω2+C0]=0 | (5.7) |
(note that A20−B20=0), where
C3=A24, C2=−2A2A4+A23, C1=2A0A4+A22−2A1A3−B22, C0=−2A0A2+A21+2B0B2−B21. |
By Lemma 3.1, we can rule out Ω=0. Hence, we obtain
C3(Ω2)3+C2(Ω2)2+C1Ω2+C0=0. | (5.8) |
As in Section 4.1, we define H(x):=C3x3+C2x2+C1x+C0. If H(x)=0 has a positive root x∗>0, then Ω=√x∗ satisfies (5.7). To find such x∗, we investigate the signs of coefficients in (5.8). We prove the following lemma:
Lemma 5.3. C2>0 and C3>0 for all τ≥0.
Proof. It is obvious that C3=(pQ+1)2≥1>0 for all τ≥0. On C2, we have
C2=−2A2A4+A23=−2{[p(p−q)+Λ∗q]pQ+Λ∗p−(p−q)2}(pQ+1)+[(2p−q)pQ+p]2=−2{p2(p−q)Q−(p−q)2}(pQ+1)−2Λ∗p(qQ+1)(pQ+1)+[(2p−q)pQ+p]2. | (5.9) |
Recalling that p−q=k+μ+Λ∗>Λ∗ and qQ+1=eqτ>0, we obtain
C2>−2{p2(p−q)Q−(p−q)2}(pQ+1)−2(p−q)p(qQ+1)(pQ+1)+[(2p−q)pQ+p]2={−2[p(p−q)+(p−q)q]+(2p−q)2}(pQ)2+{−2[p(p−q)+(p−q)(p+q)−(p−q)2]+2p(2p−q)}pQ−2[p(p−q)−(p−q)2]+p2=[2(p−q)2+q2](pQ)2+2[(p−q)2+q2]pQ+(p−q)2+q2≥(p−q)2+q2>0, | (5.10) |
for all τ≥0. This completes the proof.
By Lemma 5.3, if C0<0 for all τ≥0, then a similar argument as in the proof of Lemma 4.2 gives the existence of the unique Ω>0 satisfying (5.8). However, unlike the case of Λ∗=γ in Section 4, C0<0 for all τ≥0 does not hold in general. To clarify this point, we investigate a special case where the following additional condition is satisfied:
(A6) γ≫k+μ.
For example, if the reduction rate k of infectivity is small, then (A6) is not so unrealistic because, in many human infectious diseases, the infection period is much shorter than the average life span (that is, γ≫μ). Under assumption (A6), p≈γ, and coefficients in (5.4) can be rewritten as
A4=γQ+1,A3=(2γ−q)γQ+γ,A2=[γ(γ−q)+Λ∗q]γQ+Λ∗γ−(γ−q)2=(γ−q)[(γ+q)γQ+γ−(γ−q)]=(γ−q)[(γ+q)γQ+q],A1=−γ(γ−q)2+Λ∗(2γ−q)γ(qQ+1)=(γ−q)[−γ(γ−q)+(2γ−q)γ(qQ+1)]=γ(γ−q)2qQ+(γ−q)γ2(qQ+1),A0=(γ−q)2γ2(qQ+1),B2=γ(γ−q)(1−Λ∗Q)=(γ−q)[γ−(γ−q)γQ],B1=γ(γ−q)2−Λ∗γ(γ−q)[2+(γ+q)Q]=γ(γ−q)2[−1+(γ+q)Q],B0=−A0 |
(note that Λ∗=γ−q>0). We next prove the following lemma on the sign of C0:
Lemma 5.4. Suppose that (A6) holds. Then, the following properties hold:
(ⅰ) If |q|<γ/√2, then C0<0 for all τ≥0. In particular, C0 is monotone decreasing for τ≥0.
(ⅱ) If q>(√3−1)γ or q<−(√3+1)γ, then C0>0 for all τ≥0. In particular, C0 is monotone increasing for τ≥0.
Proof. Under assumption (A6), C0 can be calculated as
C0=−2A0(A2+B2)+A21−B21=−2(γ−q)3γ2(qQ+1)(2qγQ+q+γ)+γ2(γ−q)2{[(γ−q)qQ+γ(qQ+1)]2−(γ−q)2[(γ+q)Q−1]2}=γ2(γ−q)2{2(q−γ)[2q2γQ2+(q2+3qγ)Q+(q+γ)]+(6γ2q2−4γq3−γ4)Q2+(−2γ3+6γ2q−2q3)Q+2qγ−q2}=γ2(γ−q)2[(2q2−γ2)(γQ)2+2(2q2−γ2)γQ+(q+γ)2−3γ2]. | (5.11) |
If |q|<γ/√2, then 2q2−γ2<0, and thus,
C0<γ2(γ−q)2[(q+γ)2−3γ2]=γ2(γ−q)2[q−(√3−1)γ][q+(√3+1)γ]<0, |
for all τ≥0 (note that √3+1>√3−1>1/√2). The second assertion follows from (5.11) and the fact that ∂Q/∂τ=eqτ>0. This proves (ⅰ).
If q>(√3−1)γ or q<−(√3+1)γ, then 2q2−γ2>0 (note that √3−1>1/√2), and thus,
C0>γ2(γ−q)2[(q+γ)2−3γ2]=γ2(γ−q)2[q−(√3−1)γ][q+(√3+1)γ]>0, |
for all τ≥0. The second assertion follows in a similar way as in (ⅰ). This proves (ⅱ).
Figure 5 shows an example of each case in Lemma 5.4. (k,μ,γ)=(0.01,0.01,1) is fixed so that γ≫k+μ. In Figure 5(a), q=0.95γ/√2, and hence, |q|<γ/√2 holds. In this case, as stated in Lemma 5.4 (ⅰ), we can check that C0=H(0) is negative and monotone decreasing for each τ≥0. By Lemma 5.3, as in Lemma 4.2, there always exists a unique x∗>0 such that H(x∗)=0, and hence, Ω=√x∗ satisfies (5.8). In addition, one can see that H′(x∗)>0.
On the other hand, in Figure 5(b), q=1.1(√3−1)γ>(√3−1)γ. As stated in Lemma 5.4 (ⅱ), we can check that C0=H(0) is positive and monotone increasing for each τ≥0. As shown in this figure, there can exist two positive numbers x∗+>0 and x∗−>0 (x∗+>x∗−) such that H(x∗±)=0. In this case, (5.8) has two positive solutions Ω=√x∗±. In addition, one can see that H′(x∗+)>0 and H′(x∗−)<0.
Note that, as in Section 4, (5.8) is a necessary condition for λ=±iΩ to be a pair of simple pure imaginary roots of the characteristic Eq (5.4). From (5.6), we have
{cosΩτ=(A4Ω4−A2Ω2+A0)(B2Ω2−B0)+(A3Ω3−A1Ω)B1Ω(B2Ω2−B0)2+B21Ω2=:Φ,sinΩτ=−(A4Ω4−A2Ω2+A0)B1Ω+(A3Ω3−A1Ω)(B2Ω2−B0)(B2Ω2−B0)2+B21Ω2=:Ψ, | (5.12) |
and define Θ∈(0,2π] by
Θ:={arccosΦ,Ψ>0,2π−arccosΦ,Ψ≤0. |
It then follows from (5.12) that Ωτ=Θ. For each τ≥0, let F(τ):=Θ(τ)/Ω(τ). Our aim is then to show the existence of a positive fixed point F(τc)=τc>0, which implies that λ=±iΩ(τc) is a pair of simple pure imaginary roots of the characteristic Eq (5.4). To this end, we now show the following lemma:
Lemma 5.5. Suppose that (A6) holds. For coefficients C0,C1,C2 and C3, it holds that
limτ→∞1(γQ)2(C0C1C2C3)=(γ2(γ−q)2(2q2−γ2)−2(γ−q)[(γ−q)γq+q3]2(γ−q)2+q21). |
Proof. Note that limτ→∞Q=∞. It then follows that
limτ→∞C3(γQ)2=limτ→∞(γQ+1)2(γQ)2=1. |
From (5.11), it follows that
limτ→∞C0(γQ)2=limτ→∞γ2(γ−q)2[(2q2−γ2)+2(2q2−γ2)γQ+(q+γ)2−3γ2(γQ)2]=γ2(γ−q)2(2q2−γ2). |
Moreover, replacing p and Λ∗ in (5.9) by γ and γ−q, respectively, we can perform a similar calculation as in (5.10) and obtain
limτ→∞C2(γQ)2=limτ→∞[2(γ−q)2+q2+2(γ−q)2+2q2γQ+(γ−q)2+q2(γQ)2]=2(γ−q)2+q2. |
For C1, we have
C1=2A0A4+A22−2A1A3−B22=2(γ−q)2γ2(qQ+1)(γQ+1)+(γ−q)2[(γ+q)γQ+q]2−2γ(γ−q)[(γ−q)qQ+γ(qQ+1)][(2γ−q)γQ+γ]−(γ−q)2[γ−(γ−q)γQ]2=2(γ−q)γ2(qQ+1)[(γ−q)(γQ+1)−(2γ−q)γQ−γ]+(γ−q)2[4γq(γQ)2+2(γ2+q2)γQ+q2−γ2]−2(γ−q)2qγQ[(2γ−q)γQ+γ]=−2(γ−q)γ2(qQ+1)(γ2Q+q)+(γ−q)2[4γq(γQ)2+2(γ2+q2)γQ+q2−γ2]−2(γ−q)2qγQ[(2γ−q)γQ+γ]=2(γ−q)[−γ2q+2(γ−q)γq−(γ−q)q(2γ−q)](γQ)2+2(γ−q)[−(q2+γ2)γ+(γ−q)(γ2+q2)−(γ−q)qγ]γQ+(γ−q)[−2γ2q+(γ−q)(q2−γ2)]=−2(γ−q)[(γ−q)γq+q3](γQ)2−2(γ−q)[(γ−q)γq+(γ2+q2)q]γQ−(γ−q)[(γ−q)γq+γ3+q3]. |
We then have limτ→∞C1/(γQ)2=−2(γ−q)[(γ−q)γq+q3]. This completes the proof.
Using Lemmas 5.3–5.5, we prove the following proposition on the existence of a pair of simple pure imaginary roots for |q|<γ/√2:
Proposition 5.2. Suppose that (A6) holds, and |q|<γ/√2. Then, there exists a τc>0 such that λ=±iΩ(τc) is a pair of simple pure imaginary roots of the characteristic Eq (5.4).
Proof. By Lemmas 5.3 and 5.4, for each τ≥0, the positive Ω(τ)>0 uniquely exists. Hence, we have F(0)=Θ(0)/Ω(0)>0. As in the proof of Proposition 4.1, by the continuity, it suffices to show that limτ→∞F(τ)<∞.
Let {τn}∞n=1 be an increasing sequence in (0,∞), and let Ωn:=Ω(τn) and Qn:=Q(⋅,τn). By dividing both sides of (5.8) by (γQn)2, we have
C3(γQn)2(Ω2n)3+C2(γQn)2(Ω2n)2+C1(γQn)2Ω2n+C0(γQn)2=0. |
By Lemma 5.5, we see that {Ωn}∞n=1 converges to Ω∞, which is the unique positive root of the following equation:
(Ω2∞)3+[2(γ−q)2+q2](Ω2∞)2−2(γ−q)[(γ−q)γq+q3]Ω2∞+γ2(γ−q)2(2q2−γ2)=0. |
Thus, we have limτ→∞F(τ)≤2π/Ω∞<∞. This completes the proof.
For q>(√3−1)γ or q<−(√3+1)γ, by Lemma 5.4 (ⅱ), C0>0 for all τ≥0, and hence, H(x)=0 may have multiple positive roots x∗±>0 such that H′(x∗+)>0 and H′(x∗−)<0 (see Figure 5(b)). In this case, it seems difficult to show analytically the existence of a pair of simple pure imaginary roots. Instead, we will investigate it numerically in Section 5.3.
As in Section 4.2, we investigate the transversality condition of a Hopf bifurcation. Let G(τ):=τ−F(τ).
Lemma 5.6. Suppose that there exists a τc>0 such that G(τc)=0. Then, the characteristic Eq (5.4) has a pair of simple pure imaginary roots λ=±iΩ(τc)=±iΩc, and
sign{dReλdτ|λ=iΩc}=sign{H′(Ω2c)}sign{G′(τc)}. | (5.13) |
Proof. As in the proof of Proposition 4.2, we have
sign{dReλdτ|λ=iΩc}=sign{∂Y(Ωc)∂ω} sign{G′(τc)}, | (5.14) |
where Y(Ω) is defined by the left-hand side of (5.7):
Y(Ω):=Ω2[C3(Ω2)3+C2(Ω2)2+C1Ω2+C0]=Ω2H(Ω2). |
Now, we have
∂Y(Ωc)∂ω=2Ω2cH(Ω2c)+Ω2cH′(Ω2c)2Ωc=2Ω3cH′(Ω2c) |
(note that H(Ω2c)=0). As Ω3c>0, we then have
sign{∂Y(Ωc)∂ω}=sign{H′(Ω2c)}, |
and hence, (5.13) follows from (5.14). This completes the proof.
In the case of Lemma 5.4 (ⅰ), H(x)=0 has only one positive root x∗>0 such that H′(x∗)>0 (see Figure 5(a)). Therefore, by Lemma 5.6, we see that if λ=±iΩc=±i√x∗ is a pair of simple pure imaginary roots of (5.4), then it crosses the imaginary axis from left to right. This together with Lemma 5.4 (ⅰ) and Proposition 5.2 gives the following main theorem:
Theorem 5.1. Suppose that (A6) holds, q≠0, and |q|<γ/√2. If β1 depends on τ as for (5.3), then R0>1 and Λ∗=γ−q>0 hold for all τ≥0, and there exists a τc>0 such that a pair of simple pure imaginary roots ±iΩ(τc)(=±iΩc) satisfies the characteristic Eq (5.4) and crosses the imaginary axis from left to right as τ increases over τc.
Under the condition in Theorem 5.1, there always exists a critical value τc>0 such that a Hopf bifurcation occurs, and a periodic solution arises at τ=τc. Note that, under assumption (A6), "sufficiently small |q|" in Corollary 5.1 is improved to the inequality |q|<γ/√2 in Theorem 5.1. For the case of Lemma 5.4 (ⅱ), we have the following remark:
Remark 5.1. In the case of Lemma 5.4 (ii), H(x)=0 may have two positive roots x∗+>x∗−>0 such that H′(x∗+)>0>H′(x∗−) (see Figure 5(b)). Therefore, by Lemma 5.6, we see that if λ=±iΩc=±i√x∗+ (resp. ±i√x∗−) is a pair of simple pure imaginary roots of (5.4), then it crosses the imaginary axis from left to right (resp. from right to left). In other words, λ=±i√x∗+ (resp. ±i√x∗−) can lead to the destabilization (resp. stabilization) of the endemic equilibrium E∗.
In other words, in the case of Lemma 5.4 (ⅱ), the stability switch of the endemic equilibrium E∗ can occur more than once. We numerically confirm this point in the next subsection.
Fix the following parameters:
k=μ=0.05,γ=10,p=10.1(=k+μ+γ). |
Note that they are chosen for a technical reason to confirm the validity of Theorem 5.1 and Remark 5.1, and there is no biological justification. We can regard γ≫k+μ, and thus, assumption (A6) holds. For each q∈(−∞,0)∪(0,γ) and τ≥0, set β1 as (5.3). Then, R0>1, and Λ∗=γ−q>0 holds. To investigate the stability of the endemic equilibrium E∗, set the initial condition as
S(0,a)=S∗(a)=e−Λ∗a,I(0,a)=0.9I∗(a)=0.9Λ∗q(e−Λ∗a−e−γa),a≥0. |
First, set q=0.95γ/√2≈6.7175. In this case, by Theorem 5.1, there exists a τc>0 such that a Hopf bifurcation occurs. In fact, we can calculate τc≈0.446 (see Figure 6(a)).
Figure 7(a) and (b) show that, for τ=0.4<τc, I(t,a) and Λ(t) converge to the steady states I∗(a) and Λ∗=γ−q≈3.2825, respectively.
On the other hand, Figure 7(c) and (d) show that, for τ=0.5>τc, I(t,a) and Λ(t) converge to positive periodic solutions. This indicates that a Hopf bifurcation occurs at τ=τc.
Next, set q=1.36(√3−1)γ≈9.9559. In this case, by Lemma 5.4 (ⅱ), C0>0 for all τ≥0, and hence, H(x)=0 may have two positive roots x∗+>x∗−>0 such that H′(x∗+)>0>H′(x∗−). As stated in Remark 5.1, λ=±i√x∗+ (resp. ±i√x∗−) can lead to the destabilization (resp. stabilization) of the endemic equilibrium E∗. To clarify this point, let F+(τ) and G+(τ) (resp. F−(τ) and G−(τ)) be F(τ) and G(τ) corresponding to Ω(τ)=√x∗+(τ) (resp. √x∗−(τ)), respectively. If there exists a τ+>0 (resp. τ−>0) such that G+(τ+)=0 (resp. G−(τ−)=0), then the destabilization (resp. stabilization) of the endemic equilibrium E∗ can occur at τ=τ+ (resp. τ−). In fact, we can compute F±(τ) and G±(τ) as shown in Figure 6(b) and obtain τ+≈2.55 and τ−≈8.7. That is, we can predict that the endemic equilibrium E∗ is stable for τ∈[0,τ+), is unstable for τ∈(τ+,τ−) and becomes stable again when τ increases over τ−. Indeed, in Figure 8(a), the force of infection Λ(t) converges to the positive steady state Λ∗=γ−q≈0.0441 for τ=2<τ+, whereas in Figure 8(b), τ=3>τ+, and Λ(t) converges to a periodic solution.
In Figure 8(c), for τ=8.2<τ−, Λ(t) converges to a periodic solution, whereas in Figure 8(d), for τ=9.2>τ−, Λ(t) converges to the positive steady state. That is, the stability switch of the endemic equilibrium E∗ occurs twice at τ=τ+ and τ−.
In this paper, we have studied the local stability of the endemic equilibrium in a chronological age-structured SIR epidemic model with age-dependent infectivity. We assumed that the transmission rate is a shifted exponential function and investigated the possibility of a Hopf bifurcation regarding the infimum of the support of the transmission rate as a bifurcation parameter. We have shown that, if the distance between the force of infection at the endemic equilibrium and the removal rate is zero or sufficiently small (|q|≪1), then there always exists a critical value of the bifurcation parameter at which a Hopf bifurcation occurs. Furthermore, in a special case where the removal rate is sufficiently larger than the sum of the mortality rate and the reduction rate of infectivity, we have obtained a specific inequality (|q|<γ/√2) for which a similar critical value for a Hopf bifurcation always exists. We have performed numerical simulations and observed bifurcations of a stable periodic solution from the endemic equilibrium. On the other hand, for the case where q>(√3−1)γ, we have numerically confirmed that the stability switch of the endemic equilibrium can occur multiple times.
Our results have given a partial answer to a question of the possibility of a Hopf bifurcation in a chronological age-structured SIR epidemic model with age-dependent infectivity, which was raised in [15]. As our results are restricted to a special case where the transmission rate is a shifted exponential function, the study of other cases would be interesting future work. In particular, although we disregarded the age-dependent susceptibility for the sake of simplicity in the analysis, it would make the model more realistic because the assumption of the shifted exponential function could be suitable for some sexually transmitted diseases for which people under a certain age do not have the infectivity and susceptibility. It is an open problem whether a Hopf bifurcation still occurs if we introduce the age-dependent susceptibility to our model. Although it might be easily checked by numerical simulations, the analytical proof may be a more challenging task because it may be difficult to obtain a concrete characteristic equation like (4.4) when the force of infection depends on the age of the susceptible population.
Although our work in this paper was motivated by the mathematical analysis, periodic solutions in autonomous systems like our model could help in understanding the mechanism of the non-seasonal recurrent outbreaks which have been observed in many diseases such as measles. The application of our results to epidemiological considerations would also be important future work.
We deeply appreciate the editor and the anonymous referees for their valuable and constructive comments that helped us to improve the manuscript. T. Kuniya was supported by the Japan Society for the Promotion of Science (JSPS) [grant numbers 19K14594, 23K03214]. H. Inaba was supported by the Japan Society for the Promotion of Science (JSPS) [grant number 22K03433].
The authors declare there is no conflict of interest.
[1] |
Havelaar AH, Kirk MD, Torgerson PR, et al. (2010) World health organization global estimates and regional comparisons of the burden of foodborne disease in 2010. PLOS Med 12: e1001923. doi: 10.1371/journal.pmed.1001923
![]() |
[2] |
Byzova NA, Vinogradova SV, Porotikova EV, et al. (2018) Lateral flow immunoassay for rapid detection of grapevine leafroll-associated virus. Biosensors (Basel) 8: E111. doi: 10.3390/bios8040111
![]() |
[3] |
Anfossi L, Di Nardo F, Cavalera S, et al. (2018) Multiplex lateral flow immunoassay: an overview of strategies towards high-throughput point-of-need testing. Biosensors (Basel) 9: E2. doi: 10.3390/bios9010002
![]() |
[4] |
Kim H, Chung DR, Kang M (2019) A new point-of-care test for the diagnosis of infectious diseases based on multiplex lateral flow immunoassays. The Analyst 144: 2460-2466. doi: 10.1039/C8AN02295J
![]() |
[5] | World Health Organization (2010) Global estimates and regional comparisons of the burden of foodborne disease in 2010. PLoS Med 12: e1001923. |
[6] |
Urusov AE, Zherdev AV, Dzantiev BB (2019) Towards lateral flow quantitative assays: detection approaches. Biosensors (Basel) 9: 89. doi: 10.3390/bios9030089
![]() |
[7] |
Cheng N, Song Y, Zeinhom MM, et al. (2017) Nanozyme-mediated dual immunoassay integrated with smartphone for use in simultaneous detection of pathogens. ACS Appl Mater Interfaces 9: 40671-40680. doi: 10.1021/acsami.7b12734
![]() |
[8] |
Zarei M (2018) Infectious pathogens meet point-of-care diagnostics. Biosens Bioelectron 106: 193-203. doi: 10.1016/j.bios.2018.02.007
![]() |
[9] |
Yalow RS, Berson SA (1960) Immunoassay of endogenous plasma insulin in man. J Clin Invest 39: 1157-1175. doi: 10.1172/JCI104130
![]() |
[10] |
Mak WC, Beni V, Turner APF (2016) Lateral-flow technology: From visual to instrumental. Trends Analyt Chem 79: 297-305. doi: 10.1016/j.trac.2015.10.017
![]() |
[11] |
McPartlin DA, O'Kennedy RJ (2014) Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: Potential and limitations. Expert Rev Mol Diagn 14: 979-998. doi: 10.1586/14737159.2014.960516
![]() |
[12] |
Fu X, Wen J, Li J, et al. (2019) Highly sensitive detection of prostate cancer specific PCA3 mimic DNA using SERS-based competitive lateral flow assay. Nanoscale 11: 15530-15536. doi: 10.1039/C9NR04864B
![]() |
[13] |
Zhao Y, Wang HR, Zhang PP, et al. (2016) Rapid multiplex detection of 10 foodborne pathogens with an up-converting phosphor technology-based 10-channel lateral flow assay. Sci Rep 6: 21342. doi: 10.1038/srep21342
![]() |
[14] |
Sastre P, Gallardo C, Monedero A, et al. (2016) Development of a novel lateral flow assay for detection of African swine fever in blood. BMC Vet Res 12: 206. doi: 10.1186/s12917-016-0831-4
![]() |
[15] |
Jones D, Glogowska M, Locock L, et al. (2016) Embedding new technologies in practice–a normalization process theory study of point of care testing. BMC Health Serv Res 16: 591. doi: 10.1186/s12913-016-1834-3
![]() |
[16] |
Kozel TR, Burnham-Marusich AR (2017) Point-of-care testing for infectious diseases: past, present, and future. J Clin Microb 55: 2313-2320. doi: 10.1128/JCM.00476-17
![]() |
[17] |
Kim C, Yoo YK, Han SI, et al. (2017) Battery operated preconcentration-assisted lateral flow assay. Lab Chip 17: 2451-2458. doi: 10.1039/C7LC00036G
![]() |
[18] |
Kim H, Chung DR, Kang M (2019) A new point-of-care test for the diagnosis of infectious diseases based on multiplex lateral flow immunoassays. Analyst 144: 2460-2466. doi: 10.1039/C8AN02295J
![]() |
[19] |
Gitonga LK, Boru WG, Kwena A, et al. (2017) Point of care testing evaluation of lateral flow immunoassay for diagnosis of cryptococcus meningitis in HIV-positive patients at an urban hospital in Nairobi, Kenya, 2017. BMC Res Notes 12: 797. doi: 10.1186/s13104-019-4829-4
![]() |
[20] |
Kumar S, Bhushan P, Krishna V, et al. (2018) Tapered lateral flow immunoassay-based point-of-care diagnostic device for ultrasensitive colorimetric detection of dengue NS1. Biomicrofluidics 12: 034104. doi: 10.1063/1.5035113
![]() |
[21] |
Anfossi L, Di Nardo F, Cavalera S, et al. (2018) Multiplex lateral flow immunoassay: an overview of strategies towards high-throughput point-of-need testing. Biosensors (Basel) 9: E2. doi: 10.3390/bios9010002
![]() |
[22] |
Banerjee R, Jaiswal A (2018) Recent advances in nanoparticle-based lateral flow immunoassay as a point-of-care diagnostic tool for infectious agents and diseases. Analyst 143: 1970-1996. doi: 10.1039/C8AN00307F
![]() |
[23] |
Safenkova IV, Panferov VG, Panferova NA, et al. (2019) Alarm lateral flow immunoassay for detection of the total infection caused by the five viruses. Talanta 95: 739-744. doi: 10.1016/j.talanta.2018.12.004
![]() |
[24] |
Zhao Y, Zhang Q, Meng Q, et al. (2017) Quantum dots-based lateral flow immunoassay combined with image analysis for semiquantitative detection of IgE antibody to mite. Int J Nanomedicine 12: 4805-4812. doi: 10.2147/IJN.S134539
![]() |
[25] |
Jørgensen CS, Uldum SA, Sørensen JF, et al. (2015) Evaluation of a new lateral flow test for detection of Streptococcus pneumoniae and Legionella pneumophila urinary antigen. J Microbiol Methods 116: 33-36. doi: 10.1016/j.mimet.2015.06.014
![]() |
[26] |
Rohrman BA, Leautaud V, Molyneux E, et al. (2012) A lateral flow assay for quantitative detection of amplified HIV-1 RNA. PLoS One 7: e45611. doi: 10.1371/journal.pone.0045611
![]() |
[27] |
Boisen ML, Oottamasathien D, Jones AB, et al. (2015) Development of prototype filovirus recombinant antigen immunoassays. J Infect Dis 212: 359-367. doi: 10.1093/infdis/jiv353
![]() |
[28] |
Nielsen K, Yu WL, Kelly L, et al. (2008) Development of a lateral flow assay for rapid detection of bovine antibody to Anaplasma marginale. J Immunoassay Immunochem 29: 10-18. doi: 10.1080/15321810701734693
![]() |
[29] |
Kamphee H, Chaiprasert A, Prammananan T, et al. (2015) Rapid molecular detection of multidrug-resistant tuberculosis by PCR-nucleic acid lateral flow immunoassay. PLos One 10: e0137791. doi: 10.1371/journal.pone.0137791
![]() |
[30] |
Helfmann J, Netz UJ (2015) Sensors in diagnostics and monitoring. Photonics Lasers Med 4: 36-42. doi: 10.1515/plm-2015-0012
![]() |
[31] |
You M, Lin M, Gong Y, et al. (2017) Household fluorescent lateral flow strip platform for sensitive and quantitative prognosis of heart failure using dual-color upconversion nanoparticles. ACS Nano 11: 6261-6270. doi: 10.1021/acsnano.7b02466
![]() |
[32] |
Pilavaki E, Demosthenous A (2017) Optimized Lateral Flow Immunoassay Reader for the Detection of Infectious Diseases in Developing Countries. Sensors (Basel) 17: E2673. doi: 10.3390/s17112673
![]() |
[33] |
Kim C, Yoo YK, Han SI, et al. (2017) Battery operated preconcentration-assisted lateral flow assay. Lab Chip 17: 2451-2458. doi: 10.1039/C7LC00036G
![]() |
[34] |
Naidoo N, Ghai M, Moodley K, et al. (2017) Modified RS-LAMP assay and use of lateral flow devices for rapid detection of Leifsonia xyli subsp. xyli. Lett Appl Microbiol 65: 496-503. doi: 10.1111/lam.12799
![]() |
[35] |
Xiao W, Huang C, Xu F, et al. (2018) A simple and compact smartphone-based device for the quantitative readout of colloidal gold lateral flow immunoassay strips. Sens Actuators B Chem 266: 63-70. doi: 10.1016/j.snb.2018.03.110
![]() |
[36] |
Nelis D, Bura L, Zhao Y, et al. (2019) The Efficiency of Color Space Channels to Quantify Color and Color Intensity Change in Liquids, pH Strips, and Lateral Flow Assays with Smartphones. Sensors (Basel) 19: E5104. doi: 10.3390/s19235104
![]() |
[37] |
Schwenke KU, Spiehl D, Krauße M, et al. (2019) Analysis of free chlorine in aqueous solution at very low concentration with lateral flow tests. Sci Rep 9: 17212. doi: 10.1038/s41598-019-53687-0
![]() |
[38] |
Borges M, Araújo J (2019) False-negative result of serum cryptococcal antigen lateral flow assay in an HIV-infected patient with culture-proven cryptococcaemia. Med Mycol Case Rep 26: 64-66. doi: 10.1016/j.mmcr.2019.10.009
![]() |
[39] |
Foysal KH, Seo SE, Kim MJ, et al. (2018) Analyte Quantity Detection from Lateral Flow Assay Using a Smartphone. Sensors (Basel) 19: E4812. doi: 10.3390/s19214812
![]() |
[40] |
Romeo A, Leunga T, Sánchez S (2016) Smart biosensors for multiplexed and fully integrated point-of-care diagnostics. Lab Chip 16: 1957-1961. doi: 10.1039/C6LC90046A
![]() |
[41] |
Lee S, Mehta S, Erickson D (2016) Two-Color Lateral Flow Assay for Multiplex Detection of Causative Agents Behind Acute Febrile Illnesses. Anal Chem 88: 8359-8363. doi: 10.1021/acs.analchem.6b01828
![]() |
[42] |
Yen CW, de Puig H, Tam JO, et al. (2015) Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses. Lab Chip 5: 1638-1641. doi: 10.1039/C5LC00055F
![]() |
[43] |
Edwards KA, Korff R, Baeumner AJ (2017) Liposome-Enhanced Lateral-Flow Assays for Clinical Analyses. Methods Mol Biol 1571: 407-434. doi: 10.1007/978-1-4939-6848-0_25
![]() |
[44] |
Koczula K, Gallotta A (2016) Lateral flow assays. Essays Biochem 60: 111-120. doi: 10.1042/EBC20150012
![]() |
[45] | Guo C, Zhong LL, Yi HL, et al. (2016) Clinical value of fluorescence lateral flow immunoassay in diagnosis of influenza A in children. Zhongguo Dang Dai Er Ke Za Zhi 18: 1272-1276. |
[46] |
Berger P, Sturgeon C (2014) Pregnancy testing with hCG-future prospects. Trends Endocrinol. Metab 25: 637-648. doi: 10.1016/j.tem.2014.08.004
![]() |
[47] |
Lu F, Wang KH, Lin Y (2005) Rapid, quantitative and sensitive immunochromatographic assay based on stripping voltammetric detection of a metal ion label. Analyst 130: 1513-1517. doi: 10.1039/b507682j
![]() |
[48] |
Campbell JP, Heaney JL, Shemar M, et al. (2017) Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clin Chem Lab Med 55: 424-434. doi: 10.1515/cclm-2016-0194
![]() |
[49] |
Pilavaki E, Demosthenous A (2017) Optimized lateral flow immunoassay reader for the detection of infectious diseases in developing countries. Sensors (Basel) 17: E2673. doi: 10.3390/s17112673
![]() |
[50] |
Hsieh HV, Dantzler JL, Weigl BH, et al. (2017) Analytical tools to improve optimization procedures for lateral flow assays. Diagnostics (Basel) 7: E29. doi: 10.3390/diagnostics7020029
![]() |
[51] |
Tran TV, Nguyen BV, Nguyen TTP, et al. (2019) Development of a highly sensitive magneto-enzyme lateral flow immunoassay for dengue NS1 detection. PeerJ 7: e7779. doi: 10.7717/peerj.7779
![]() |
[52] |
Chaterji S, Allen JC, Chow A, et al. (2011) Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am J Trop Med Hyg 84: 224-228. doi: 10.4269/ajtmh.2011.10-0316
![]() |
[53] |
Rong Z, Wang Q, Sun N, et al. (2019) Smartphone-based fluorescent lateral flow immunoassay platform for highly sensitive point-of-care detection of Zika virus nonstructural protein 1. Anal Chim Acta 1055: 140-147. doi: 10.1016/j.aca.2018.12.043
![]() |
[54] | Kosasih H, Widjaja S, Surya E, et al. (2012) Evaluation of two IgM rapid immunochromatographic tests during circulation of Asian lineage chikungunya virus. Southeast Asian J Trop Med Public Health 43: 55-61. |
[55] |
Escadafal C, Faye O, Sall AA, et al. (2014) Rapid molecular assays for the detection of yellow fever virus in low-resource settings. PLoS Negl Trop Dis 8: e2730. doi: 10.1371/journal.pntd.0002730
![]() |
[56] |
Wonderly B, Jones S, Gatton ML, et al. (2019) Comparative performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014–2016 Ebola epidemic in West Africa. PLoS One 14: e0212113. doi: 10.1371/journal.pone.0212113
![]() |
[57] |
Si J, Li J, Zhang L, et al. (2019) A signal amplification system on a lateral flow immunoassay detecting for hepatitis e-antigen in human blood samples. J Med Virol 91: 1301-1306. doi: 10.1002/jmv.25452
![]() |
[58] |
Nakagiri I, Tasaka T, Okai M, et al. (2019) Screening for human immunodeficiency virus using a newly developed fourth generation lateral flow immunochromatography assay. J Virol Methods 274: 113746. doi: 10.1016/j.jviromet.2019.113746
![]() |
[59] |
Karaman E, Ilkit M, Kuşçu F (2019) Identification of Cryptococcus antigen in human immunodeficiency virus-positive Turkish patients by using the Dynamiker® lateral flow assay. Mycoses 62: 961-968. doi: 10.1111/myc.12969
![]() |
[60] |
Morioka K, Fukai K, Yosihda K, et al. (2015) Development and evaluation of a rapid antigen detection and serotyping lateral flow antigen detection system for foot-and-mouth disease virus. PLoS ONE 10: e0134931. doi: 10.1371/journal.pone.0134931
![]() |
[61] |
Wang C, Wang C, Wang X, et al. (2019) Magnetic SERS Strip for Sensitive and Simultaneous Detection of Respiratory Viruses. ACS Appl Mater Interfaces 11: 19495-19505. doi: 10.1021/acsami.9b03920
![]() |
[62] |
El-Tholoth M, Branavan M, Naveenathayalan A, et al. (2019) Recombinase polymerase amplification-nucleic acid lateral flow immunoassays for Newcastle disease virus and infectious bronchitis virus detection. Mol Biol Rep 46: 6391-6397. doi: 10.1007/s11033-019-05085-y
![]() |
[63] |
Huang YH, Yu KY, Huang SP, et al. (2020) Development of a Nucleic Acid Lateral Flow Immunoassay for the Detection of Human Polyomavirus BK. Diagnostics (Basel) 10: E403. doi: 10.3390/diagnostics10060403
![]() |
[64] |
Salminen T, Knuutila A, Barkoff AM, et al. (2018) A rapid lateral flow immunoassay for serological diagnosis of pertussis. Vaccine 36: 1429-1434. doi: 10.1016/j.vaccine.2018.01.064
![]() |
[65] |
Hwang J, Lee S, Choo J (2016) Application of a SERS-based lateral flow immunoassay strip for the rapid and sensitive detection of staphylococcal enterotoxin B. Nanoscale 8: 11418-11425. doi: 10.1039/C5NR07243C
![]() |
[66] |
Eryılmaz M, Acar Soykut E, Çetin D, et al. (2019) -based rapid assay for sensitive detection of Group A Streptococcus by evaluation of the swab sampling technique. Analyst 144: 3573-3580. doi: 10.1039/C9AN00173E
![]() |
[67] |
Prentice KW, DePalma L, Ramage JG, et al. (2019) Comprehensive Laboratory Evaluation of a Lateral Flow Assay for the Detection of Yersinia pestis. Health Secur 17: 439-453. doi: 10.1089/hs.2019.0094
![]() |
[68] |
Wang J, Katani R, Li L, et al. (2016) Rapid detection of Escherichia coli O157 and shiga toxins by lateral flow immunoassays. Toxins 8: 92. doi: 10.3390/toxins8040092
![]() |
[69] |
Wu Z (2019) Simultaneous detection of Listeria monocytogenes and Salmonella typhimurium by a SERS-Based lateral flow immunochromatographic assay. Food Anal Methods 12: 1086-1091. doi: 10.1007/s12161-019-01444-4
![]() |
[70] |
El-Shabrawi M, El-Aziz NA, El-Adly TZ, et al. (2018) Stool antigen detection versus 13C-urea breath test for non-invasive diagnosis of pediatric Helicobacter pylori infection in a limited resource setting. Arch Med Sci 14: 69-73. doi: 10.5114/aoms.2016.61031
![]() |
[71] |
Machiesky L, Côté O, Kirkegaard LH, et al. (2019) A rapid lateral flow immunoassay for identity testing of biotherapeutics. J Immunol Methods 474: 112666. doi: 10.1016/j.jim.2019.112666
![]() |
[72] |
Anfossi L, Di Nardo F, Cavalera S, et al. (2018) Multiplex Lateral Flow Immunoassay: An Overview of Strategies towards High-throughput Point-of-Need Testing. Biosensors (Basel) 9: 2. doi: 10.3390/bios9010002
![]() |
[73] |
Nouvellet P, Garske T, Mills HL, et al. (2015) The role of rapid diagnostics in managing Ebola epidemics. Nature 528: S109-S116. doi: 10.1038/nature16041
![]() |
[74] |
Hassan AHA, Bergua JF, Morales-Narváez E, et al. (2019) Validity of a single antibody-based lateral flow immunoassay depending on graphene oxide for highly sensitive determination of E. coli O157:H7 in minced beef and river water. Food Chem 297: 124965. doi: 10.1016/j.foodchem.2019.124965
![]() |
[75] | Lai CC, Wang CY, Ko WC (2020) In vitro diagnostics of coronavirus disease 2019: Technologies and application. J Microbiol Immunol Infect . |
[76] |
Askim JR, Suslick KS (2015) Hand-held reader for colorimetric sensor arrays. Anal. Chem 87: 7810-7816. doi: 10.1021/acs.analchem.5b01499
![]() |
[77] |
Liu J, Geng Z, Fan Z, et al. (2019) Point-of-care testing based on smartphone: The current state-of-the-art (2017–2018). Biosens Bioelectron 132: 17-37. doi: 10.1016/j.bios.2019.01.068
![]() |
[78] |
You M, Lin M, Gong Y, et al. (2017) Household fluorescent lateral flow strip platform for sensitive and quantitative prognosis of heart failure using dual-color upconversion nanoparticles. ACS Nano 11: 6261-6270. doi: 10.1021/acsnano.7b02466
![]() |
[79] |
Xiao W, Huang C, Xu F, et al. (2018) A simple and compact smartphone-based device for the quantitative readout of colloidal gold lateral flow immunoassay strips. Sens Actuators B Chem 266: 63-70. doi: 10.1016/j.snb.2018.03.110
![]() |
[80] |
Saisin L, Amarit R, Somboonkaew A, et al. (2020) Significant sensitivity improvement for camera-based lateral flow immunoassay readers. Sensors 18: 4026. doi: 10.3390/s18114026
![]() |
[81] |
Nsabimana AP, Uzabakiriho B, Kagabo DM, et al. (2018) Bringing Real-Time Geospatial Precision to HIV Surveillance Through Smartphones: Feasibility Study. JMIR Public Health Surveill 4: e11203. doi: 10.2196/11203
![]() |
[82] |
Gong Y, Zheng Y, Jin B, et al. (2019) A portable and universal upcon version nanoparticle-based lateral flow assay platform for point-of-care testing. Talanta 201: 126-133. doi: 10.1016/j.talanta.2019.03.105
![]() |
[83] |
Petrosillo N, Viceconte G, Ergonul O, et al. (2020) COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect 26: 729-734. doi: 10.1016/j.cmi.2020.03.026
![]() |
[84] |
Pfefferle S, Reucher S, Nörz D, et al. (2020) Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. Euro Surveill 25: 2000152. doi: 10.2807/1560-7917.ES.2020.25.9.2000152
![]() |
[85] |
Chu DKW, Pan Y, Cheng SMS, et al. (2020) Molecular diagnosis of a novel Coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 66: 549-555. doi: 10.1093/clinchem/hvaa029
![]() |
[86] |
Jo S, Kim S, Shin DH, et al. (2020) Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 35: 145-151. doi: 10.1080/14756366.2019.1690480
![]() |
[87] |
Yip CC, Ho CC, Chan JF, et al. (2020) Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens. Int J Mol Sci 21: 2574. doi: 10.3390/ijms21072574
![]() |
[88] | Wu JL, Tseng WP, Lin CH, et al. (2020) Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect . |
[89] |
Lu F, Wang KH, Lin Y (2005) Rapid, quantitative and sensitive immunochromatographic assay based on stripping voltammetric detection of a metal ion label. Analyst 130: 1513-1517. doi: 10.1039/b507682j
![]() |
[90] | Zhang Y, Kong H, Liu X, et al. (2018) Quantum dot-based lateral-flow immunoassay for rapid detection of rhein using specific egg yolk antibodies. Artif Cells Nanomed Biotechnol 46: 1685-1693. |
[91] |
Liu Y, Gayle AA, Wilder-Smith A, et al. (2020) The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 27: taaa021. doi: 10.1093/jtm/taaa021
![]() |
[92] |
Chen Y, Chan KH, Hong C, et al. (2016) A highly specific rapid antigen detection assay for on-site diagnosis of MERS. J Infect 73: 82-84. doi: 10.1016/j.jinf.2016.04.014
![]() |
[93] |
Bhadra S, Jiang YS, Kumar MR, et al. (2015) Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV). PLoS One 10: e0123126. doi: 10.1371/journal.pone.0123126
![]() |
[94] |
Pallesen J, Wang N, Corbett KS, et al. (2017) Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 114: E7348-E7357. doi: 10.1073/pnas.1707304114
![]() |
[95] |
Malik YS, Sircar S, Bhat S, et al. (2020) Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q 40: 68-76. doi: 10.1080/01652176.2020.1727993
![]() |
[96] | Corman VM, Landt O, Kaiser M, et al. (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25: 2000045. |
[97] |
Wu A, Peng Y, Huang B, et al. (2020) Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 27: 325-328. doi: 10.1016/j.chom.2020.02.001
![]() |
[98] |
Chen Z, Zhang Z, Zhai X, et al. (2020) Rapid and sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal Chem 92: 7226-7231. doi: 10.1021/acs.analchem.0c00784
![]() |
[99] |
Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 92: 552-555. doi: 10.1002/jmv.25728
![]() |
[100] |
Huang WE, Lim B, Hsu CC, et al. (2020) RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. Microb Biotechnol 13: 950-961. doi: 10.1111/1751-7915.13586
![]() |
[101] |
Nguyen T, Duong Bang D, Wolff A (2020) Novel Coronavirus Disease (COVID-19): paving the road for rapid detection and point-of-care ciagnostics. Micromachines (Basel) 11: 306. doi: 10.3390/mi11030306
![]() |
[102] |
Kashir J, Yaqinuddin A (2020) Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19. Med Hypotheses 141: 109786. doi: 10.1016/j.mehy.2020.109786
![]() |
[103] |
Koch T, Dahlke C, Fathi A, et al. (2020) Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis 20: 827-838. doi: 10.1016/S1473-3099(20)30248-6
![]() |
[104] |
Zhu FC, Li YH, Guan XH, et al. (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395: 1845-1854. doi: 10.1016/S0140-6736(20)31208-3
![]() |
[105] |
Alkan F, Ozkul A, Bilge-Dagalp S, et al. (2011) The detection and genetic characterization based on the S1 gene region of BCoVs from respiratory and enteric infections in Turkey. Transbound Emerg Dis 58: 179-185. doi: 10.1111/j.1865-1682.2010.01194.x
![]() |
[106] |
Pradhan SK, Kamble NM, Pillai AS, et al. (2014) Recombinant nucleocapsid protein based single serum dilution ELISA for the detection of antibodies to infectious bronchitis virus in poultry. J Virol Methods 209: 1-6. doi: 10.1016/j.jviromet.2014.08.015
![]() |
[107] |
Montesinos I, Gruson D, Kabamba B, et al. (2020) Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol 128: 104413. doi: 10.1016/j.jcv.2020.104413
![]() |
[108] | Deeks JJ, Dinnes J, Takwoingi Y, et al. (2020) Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 6: CD013652. |
[109] | Wen T, Huang C, Shi FJ, et al. (2020) Development of a lateral flow immunoassay strip for rapid detection of IgG antibody against SARS-CoV-2 virus. Analyst 10: 1039. |
[110] |
Wang Y, Hou Y, Li H, et al. (2019) A SERS-based lateral flow assay for the stroke biomarker S100-β. Mikrochim Acta 186: 548. doi: 10.1007/s00604-019-3634-z
![]() |
[111] |
Nicol T, Lefeuvre C, Serri O, et al. (2020) Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol 129: 104511. doi: 10.1016/j.jcv.2020.104511
![]() |
[112] | (2020) Johns Hopkins University Health Safety Center official website. Available from: https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html. |
[113] | (2020) Cellex Ltd. official website. Cellex qSARS-CoV-2 IgG/IgM Rapid Test. Available from: https://cellexcovid.com. |
[114] | (2020) ChemBio Ltd. official website. DPP® COVID-19 IgM/IgG System. Available from: http://chembio.com. |
[115] | (2020) Hardy diagnostics official website. Anti-SARS-CoV-2 Rapid Test. Available from: https://hardydiagnostics.com/sars-cov-2. |
[116] | (2020) Healgen Scientific LLC official website. COVID-19 Antibody Rapid Detection Kit. Available from: https://www.healgen.com/if-respiratory-covid-19. |
[117] | (2020) Hangzhou Biotest Biotech Co., Ltd official website. RightSign™ COVID-19 IgM/IgG Rapid Test Kit. Available from: https://www.healgen.com/if-respiratory-covid-19. |
[118] | (2020) Biohit Healthcare (Heifei) Co. Ltd. official website. Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit. Available from: https://www.fda.gov/media/139283/download. |
[119] | (2020) Hangzhou Laihe Biotech Co., Ltd official website. Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit. Available from: https://www.fda.gov/media/139410/download. |
[120] | (2020) Aytu Biosciences/Orient Gene Biotech official website. The COVID-19 IgG/IgM Point-of-Care Rapid Test. Available from: https://stocknewsnow.com/companynews/5035338834942348/ AYTU/101843. |
[121] |
Sajid M, Kawde AN, Daud M (2015) Designs, formats and applications of lateral flow assay: A literature review. J Saudi Chem Soc 19: 689-705. doi: 10.1016/j.jscs.2014.09.001
![]() |
[122] |
Choi JR, Hu J, Gong Y, et al. (2016) An integrated lateral flow assay for effective DNA amplification and detection at the point of care. Analyst 141: 2930-2939. doi: 10.1039/C5AN02532J
![]() |
[123] |
Kamphee H, Chaiprasert A, Prammananan T, et al. (2015) Rapid molecular detection of multidrug-resistant tuberculosis by PCR-nucleic acid lateral flow immunoassay. PLoS One 10: e0137791. doi: 10.1371/journal.pone.0137791
![]() |
[124] |
Huang YH, Yu KY, Huang SP, et al. (2020) Development of a Nucleic Acid Lateral Flow Immunoassay for the Detection of Human Polyomavirus BK. Diagnostics (Basel) 10: 403. doi: 10.3390/diagnostics10060403
![]() |
[125] |
Mens PF, de Bes HM, Sondo P, et al. (2012) Direct blood PCR in combination with nucleic acid lateral flow immunoassay for detection of Plasmodium species in settings where malaria is endemic. J Clin Microbiol 50: 3520-3525. doi: 10.1128/JCM.01426-12
![]() |
[126] |
Pecchia S, Da Lio D (2018) Development of a rapid PCR-Nucleic Acid Lateral Flow Immunoassay (PCR-NALFIA) based on rDNA IGS sequence analysis for the detection of Macrophomina phaseolina in soil. J Microbiol Methods 151: 118-128. doi: 10.1016/j.mimet.2018.06.010
![]() |
[127] |
Moers AP, Hallett RL, Burrow R, et al. (2015) Detection of single-nucleotide polymorphisms in Plasmodium falciparum by PCR primer extension and lateral flow immunoassay. Antimicrob Agents Chemother 59: 365-371. doi: 10.1128/AAC.03395-14
![]() |
[128] |
Roth JM, Sawa P, Omweri G, et al. (2018) Molecular Detection of Residual Parasitemia after Pyronaridine-Artesunate or Artemether-Lumefantrine Treatment of Uncomplicated Plasmodium falciparum Malaria in Kenyan Children. Am J Trop Med Hyg 99: 970-977. doi: 10.4269/ajtmh.18-0233
![]() |
[129] |
Rule GS, Montagna RA, Durst RA (1996) Rapid method for visual identification of specific DNA sequences based on DNA-tagged liposomes. Clinical Chemistry 42: 1206-1209. doi: 10.1093/clinchem/42.8.1206
![]() |
[130] |
Jauset-Rubio M, Svobodová M, Mairal T, et al. (2016) Ultrasensitive, rapid and inexpensive detection of DNA using paper based lateral flow assay. Sci Rep 6: 37732. doi: 10.1038/srep37732
![]() |
1. | Jordi Ripoll, Jordi Font, Numerical approach to an age-structured Lotka-Volterra model, 2023, 20, 1551-0018, 15603, 10.3934/mbe.2023696 | |
2. | Desmond Z. Lai, Julia R. Gog, Waning immunity can drive repeated waves of infections, 2024, 21, 1551-0018, 1979, 10.3934/mbe.2024088 | |
3. | Dongxue Yan, Yongxian Jin, Hui Cao, Yu Cao, Stability and Hopf Bifurcation for a delayed hand–foot–mouth disease model with continuous age-structure in the exposed class, 2025, 84, 14681218, 104310, 10.1016/j.nonrwa.2024.104310 |